
Advertise on podcast: CathMasters by CardioNerds
Rating
5from
This podcast has
22 episodes
Language
EnglishPublisher
CardioNerdsExplicit
No
Date created
2026/06/08
Latest episode
2026/10/30
Average duration
16 min.
Release period
9 days
Description
Welcome to CardioNerds CathMasters, the podcast dedicated to advancing interventional cardiology through high-quality, evidence-based, and experience-driven education. Featuring leading experts from across the field, CathMasters democratizes access to practical interventional cardiology knowledge for fellows, early-career operators, and experienced proceduralists alike.
Unlock CathMasters by CardioNerds podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from CathMasters by CardioNerds podcast
21. ACS Guidelines Question #11 with Dr. Venu Menon
2026/10/30
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 8.2 of the 2025 ACS Guidelines.
The question is asked by Johns Hopkins pre-medical undergraduate and CardioNerds Academy Intern Joshua Khorsandi, answered first by University of Wisconsin cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Shikha Jha, and then by expert faculty Dr. Venu Menon.
Dr. Menon is the Section Head of Clinical Cardiology, Director of the Cardiac Intensive Care Unit, and Program Director of Cardiology Fellowship at the Cleveland Clinic. He is the Mehdi Razavi Endowed Chair and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. He was also a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
A 58-year-old man with a past medical history of hypertension, hyperlipidemia, schizophrenia, atrial fibrillation (on apixaban), and prior tobacco use presents to the emergency department with chest tightness. ECG shows ST elevations in leads II, III, and aVF with reciprocal depressions in leads I and aVL. Emergency coronary angiography demonstrates 100% occlusion of the proximal RCA, and he undergoes PCI. Transthoracic echocardiogram afterward reveals normal LV function with inferior hypokinesis. On day 2, the patient experienced lightheadedness and has frequent melanic stools. His hemoglobin returns at 6 gm/dL (initial hemoglobin 11 g/dL). He undergoes EGD and colonoscopy with successful endoscopic treatment of a small gastric ulcer.
True or False: it is reasonable to administer 3-4 units of packed red blood cells for a goal Hb ≥ 10 g/dL.
True
False
Explanation
The correct answer is True – it would be reasonable to administer 3-4 units of packed red blood cells for a goal Hb ≥ 10 g/dL.
Anemia is common in patients with ACS and is associated with worse short- and long-term outcomes. Anemia is associated with adverse outcomes irrespective of whether the anemia is chronic and due to comorbid conditions, or acute and the result of bleeding related to antithrombotic therapy and/or invasive procedures. The adverse effects of anemia may be due to decreased myocardial oxygen delivery, increased myocardial oxygen demand due to increased cardiac output, or the avoidance of potentially beneficial antithrombotic drugs and/or procedures. Randomized trials in medically ill patients and those undergoing cardiac surgery have demonstrated similar or better outcomes with a restrictive transfusion strategy (targeting a blood hemoglobin level around 8 g/dL) than with a liberal transfusion strategy (targeting a blood hemoglobin level around 10 g/dL). However, randomized trial evidence for populations with ACS suggests possible clinical benefit for a more liberal transfusion strategy targeting a hemoglobin level above 10 g/dL compared with targeting a hemoglobin level above 7 g/dL to 8 g/dL
The MINT (Myocardial Ischemia and Transfusion) trial randomly assigned 3,504 patients with acute STEMI or NSTEMI and anemia with a blood hemoglobin level of 10 g/dL in patients with ACS and acute or chronic anemia to reduce cardiovascular events.
Main Takeaway
In patients with ACS and acute or chronic anemia, blood transfusion to achieve a hemoglobin level of more than 10 g/dL may be reasonable to reduce cardiovascular events.
Guideline Loc.
Section 10.2
20. ACS Guidelines Question #10 with Dr. Venu Menon
2026/10/29
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 9.2 of the 2025 ACS Guidelines.
The question is asked by Johns Hopkins pre-medical undergraduate and CardioNerds Academy Intern Joshua Khorsandi, answered first by Washington University cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Colin Martz, and then by expert faculty Dr. Venu Menon.
Dr. Menon is the Section Head of Clinical Cardiology, Director of the Cardiac Intensive Care Unit, and Program Director of Cardiology Fellowship at the Cleveland Clinic. He is the Mehdi Razavi Endowed Chair and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. He was also a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
A 72-year-old woman with past medical history significant for hypertension, hyperlipidemia, and rheumatoid arthritis is brought to the emergency department by EMS for chest pain and found to have an anterior STEMI. Coronary angiography reveals 100% occlusion of her proximal LAD. During revascularization, she develops complete heart block, so a temporary transvenous pacing wire is inserted. After the PCI, she is monitored in the CCU. Three days later, she continues to have an intermittent high-grade AV block along with shortness of breath. Transthoracic echocardiogram demonstrates mildly reduced LV function with anterior and anteroseptal hypokinesis. What is the best next step?
A
Continue to monitor with temporary transvenous pacer
B
Permanent pacemaker implantation
C
Start dopamine infusion
D
Administer atropine as needed
Explanation
The correct answer is B – permanent pacemaker implantation.
Patients with STEMI with second- or third-degree atrioventricular blocks have higher in-hospital mortality than those without high-degree atrioventricular blocks. Patients who present with ACS with complete heart block have a higher incidence of cardiogenic shock, ventricular arrhythmia, and death. In a contemporary cohort of patients with AMI, the incidence of high-degree atrioventricular block has decreased from 4.2% to 2.1%; however, increased morbidity and mortality remain despite reperfusion therapy in those with high-degree atrioventricular block. A pooled analysis of 30,000 patients found that high-degree atrioventricular block, asystole, and electromechanical dissociation are infrequent complications of NSTEMI but are associated with increased short-term mortality. High-degree atrioventricular block is not considered to be responsible for the increased mortality but is a surrogate marker of larger infarct size. Temporary pacemaker insertion in the setting of ACS in patients with high-degree atrioventricular blocks and other pacer indications has been found to improve post-discharge survival. Permanent pacemaker insertion is recommended with unresolved high-degree atrioventricular block that persists >72 hours.
The 2025 ACS guidelines give a Class 1 recommendation (LOE B-NR) for permanent pacing in patients presenting with an AMI with sustained evidence of second-degree Mobitz type II atrioventricular block, high-grade atrioventricular block, alternating bundle-branch block, or third-degree atrioventricular block (persistent orinfranodal).
This patient has had more than 72 hours of ongoing high-grade heart block post-MI. Continuous use of temporary transvenous pacing (answer choice A), dopamine infusion (answer choice C), or atropine (answer choice D) will not permanently treat the bradyarrhythmia and hence none of these answers represents the next best treatment option for the patient.
Main Takeaway
In patients presenting with an AMI with sustained (i.e. >72 hours) evidence of second-degree Mobitz type II atrioventricular block, high-grade atrioventricular block, alternating bundle branch block or third-degree atrioventricular block (persistent or infra-nodal), permanent pacing is indicated.
Guideline Loc.
Section 9.2
19. ACS Guidelines Question #9 with Dr. Venu Menon
2026/10/28
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 9.2 of the 2025 ACS Guidelines.
The question is asked by Johns Hopkins pre-medical undergraduate and CardioNerds Academy Intern Joshua Khorsandi, answered first by University of Wisconsin cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Shikha Jha, and then by expert faculty Dr. Venu Menon.
Dr. Menon is the Section Head of Clinical Cardiology, Director of the Cardiac Intensive Care Unit, and Program Director of Cardiology Fellowship at the Cleveland Clinic. He is the Mehdi Razavi Endowed Chair and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. He was also a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
A 74-year-old man with past medical history significant for hyperlipidemia, obstructive sleep apnea, hypertension, tobacco use, type 2 diabetes mellitus, and chronic obstructive pulmonary disease presents to the emergency department with two days of chest tightness and worsening shortness of breath at rest. He is found to have ST elevations in the anterolateral leads. Emergent coronary angiography demonstrates 90% stenosis of proximal to mid LAD and he is treated with two drug-eluting stents. Transthoracic echocardiograms during hospitalization showed an LVEF of 25% with anterior and apical wall motion abnormalities. He is discharged on dual antiplatelet therapy along with metoprolol, valsartan, spironolactone, SGLT2 inhibitor, and rosuvastatin. At follow-up 3 months later, he reports home BP readings in 90s/50s mm Hg with intermittent shortness of breath and lightheadedness. Blood pressure in the office is 92/54 mmHg. ECG shows normal sinus rhythm with anterior Q waves, a narrow QRS, and no acute ST-segment or T-wave changes. Repeat transthoracic echocardiogram shows an LVEF of 30%. What is the most appropriate next step?
A
Switch valsartan to sacubitril-valsartan
B
Consider implantable cardioverter defibrillator (ICD) placement
C
Consider cardiac resynchronization therapy
D
Consider additional cardiac rehabilitation sessions
Explanation
The correct answer is B – consider implantable cardioverter defibrillator (ICD) placement.
Generally, arrhythmic complications increase both morbidity and mortality rates in patients after ACS. Patients who present with AMI with reduced LVEF (≤40%) have increased risk of new-onset atrial fibrillation, bradyarrhythmias, and ventricular arrhythmias. Ventricular arrhythmias are common after ACS and more common in patients with reduced LVEF. The MADIT II trial (Multicenter Automatic Defibrillator Implantation Trial) demonstrated a 31% reduction in all-cause mortality (HR, 0.69 [95% CI, 0.51-0.93]) for prophylactic implantation of a cardiac defibrillator in patients with an LVEF ≤30% who were at least 30 days after MI or 3 months after revascularization for MI and had an anticipated life expectancy longer than 1 year. A mortality benefit for prophylactic ICD implantation has also been shown in patients with an LVEF ≤35% and New York Heart Association class II or III HF symptoms, as well as in patients with inducible ventricular tachycardia or ventricular fibrillation and an LVEF ≤40%.
This patient has an LVEF of 48 hours and within 40 days post-MI to improve survival (LOE 2a, LOE C-EO).
Some may wonder about the use of a temporary wearable cardioverter-defibrillator after the initial presentation. In the VEST trial, this strategy did not significantly reduce the primary endpoint, a composite of sudden death or death from ventricular tachyarrhythmias at 90 days) in patients with AMI and LVEF ≤ 35%. Notably, there was a lower incidence of death from any cause in the wearable vest group compared to the no-device group and overall, greater benefit was seen in those who were compliant with the device. As such, use of a wearable cardioverter-defibrillator could be considered in high-risk patients with reduced LVEF as a bridge to consideration for the need for an ICD. Per the guidelines, in patients early after MI, usefulness of a temporary wearable cardioverter-defibrillator is uncertain in patients with an LVEF ≤35% to improve survival (COR 2b, LOE B-R).
Main Takeaway
In patients post MI, implantable cardioverter defibrillator (ICD) implantation is recommended in selected patients with an LVEF of less than or equal to 40% at least 40 days post MI and at least 90 days post revascularization to reduced death.
Guideline Loc.
Section 9.2
18. ACS Guidelines Question #8 with Dr. Venu Menon
2026/10/27
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 9.1 of the 2025 ACS Guidelines.
The question is asked by Johns Hopkins pre-medical undergraduate and CardioNerds Academy Intern Joshua Khorsandi, answered first by Washington University cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Colin Martz, and then by expert faculty Dr. Venu Menon.
Dr. Menon is the Section Head of Clinical Cardiology, Director of the Cardiac Intensive Care Unit, and Program Director of Cardiology Fellowship at the Cleveland Clinic. He is the Mehdi Razavi Endowed Chair and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. He was also a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
A 65-year-old female with no significant prior cardiac history presents to the emergency department with 3 days of chest tightness associated with shortness of breath. ECG demonstrates anterior ST-segment elevation with reciprocal depressions. Coronary angiography reveals 100% occlusion of the mid left anterior descending artery. She undergoes PCI of the LAD. Two days later, she develops worsening shortness of breath. Her HR is 115 and BP 95/50. Lungs are clear on auscultation. Cardiac examination is significant for a harsh systolic murmur at the left sternal border with a palpable thrill. Transthoracic echocardiogram showed ventricular septal rupture with left-to-right shunt and Qp:Qs estimated at 2.5:1. What is the best next step?
A
Continue medical management
B
Proceed with repeat coronary angiogram and right heart catheterization with shunt run
C
Percutaneous ventricular septal defect closure
D
Intra-aortic balloon pump placement and cardiac surgical consultation
Explanation
The correct answer is D – placement of an intra-aortic balloon pump and CT surgical consultation.
Timely reperfusion therapy has reduced the incidence of mechanical complications (ventricular septal rupture, mitral valve insufficiency due to papillary muscle infarction or rupture, or free wall rupture) after AMI. Although occasionally found incidentally, mechanical complications commonly present with recurrent or refractory chest pain or a new murmur accompanied by disproportionate heart failure, cardiogenic shock, or sudden cardiac death on clinical presentation within the first week after an AMI. Medical therapy alone is associated with high risk of early death; definitive surgical correction is frequently the treatment of choice. Mortality rates with surgery are highest in subjects with cardiogenic shock and in those requiring early emergency/urgent intervention after AMI. Observed mortality rates following delayed surgery (>7 days) are lower but patient selection and survivor bias contribute to this observation.
The 2025 ACS guidelines give a Class 2a, LOE B-NR recommendation for the use of short-term MCS devices in patients with mechanical complications of ACS for hemodynamic stabilization and bridge to surgery. The availability of temporary MCS devices has led to increasing trends for delayed surgery due to concerns for the initial degree of extensive tissue destruction. Delayed surgical intervention may enable hemodynamic stabilization, lead to recovery of end-organ injury, and promote infarct tissue healing and maturation that could facilitate definitive repair. Percutaneous approaches toward repair have been used in patients with prohibitive surgical risk or contraindications to surgery as a primary or temporizing option in the setting of acute mitral regurgitation and ventricular septal rupture andremain an evolving area of investigation. This patient is not at prohibitive risk for surgery. Select patients with mechanical complications of ACS may be considered for cardiac transplantation or durable LVAD as a primary or bailout treatment strategy to improve survival.
No RCTs evaluate the role of transfer of patients with mechanical complications after MI to dedicated centers with cardiac surgical expertise. Although overall surgical mortality is approximately 40%, it remains the treatment strategy of choice. Hemodynamic deterioration is unpredictable and can be precipitous in previously stable subjects. Consequently, transfer to a Level 1 cardiac intensive care unit (CICU) with access to various temporary MCS devices and multidisciplinary experienced teams of surgical, interventional, HF, and palliative care specialists is recommended. The guidelines give a Class 1, LOE C recommendation for management of patients with mechanical complications of ACS at centers with cardiac surgical expertise.
Main Takeaway
Patients with mechanical complications of ACS should be managed in a center with cardiac surgical expertise. In such patients, short-term MCS devices are reasonable for hemodynamical stabilization as a bridge to surgery.
Guideline Loc.
Section 9.1, Figure 9
17. ACS Guidelines Question #7 with Dr. Venu Menon
2026/10/26
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 8.2 of the 2025 ACS Guidelines.
The question is asked by Johns Hopkins pre-medical undergraduate and CardioNerds Academy Intern Joshua Khorsandi, answered first by University of Wisconsin cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Shikha Jha, and then by expert faculty Dr. Venu Menon.
Dr. Menon is the Section Head of Clinical Cardiology, Director of the Cardiac Intensive Care Unit, and Program Director of Cardiology Fellowship at the Cleveland Clinic. He is the Mehdi Razavi Endowed Chair and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. He was also a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
A 72-year-old gentleman with past medical history significant for hypertension, hyperlipidemia, type 2 diabetes, and tobacco use is brought to the ED with chief complaint of chest tightness. He is found to have ST elevations in leads V1 to V4 and is taken for emergency coronary angiography, which demonstrates 99% proximal LAD occlusion. During the procedure, he becomes hypotensive (BP 74/55 mm Hg) and tachycardic (HR 122 bpm). Norepinephrine is initiated. Right heart catheterization demonstrates elevated left and right-sided filling pressures with low cardiac index. Besides immediate revascularization, which of the following would be the best next step?
A
Cannulate for VA-ECMO
B
Placement of microaxial intravascular flow pump
C
Administration of intravenous fluid
D
Placement of an intraaortic balloon pump
Explanation
The correct answer is B – Placement of microaxial intravascular flow pump.
Cardiogenic shock is estimated to occur in approximately 10% of patients with STEMI and is associated with an early mortality rate of 40% to 50%. Several types of devices for temporary mechanical circulatory support (MCS) are available and have been studied in patients with cardiogenic shock, with variable efficacy and increased risk of vascular complications. IABP counterpulsation improves coronary perfusion and reduces cardiac afterload. It is relatively easy to use and has a smaller insertion profile (8 French), which is associated with lower rates of vascular access site complications when compared with other MCS devices. Left ventricular percutaneous microaxial flow pumps unload the LV by draining blood from the LV and pumping it to the ascending aorta. They are dependent on adequate right ventricular function to fill the LV and require adequate oxygenation of blood. VA-ECMO provides both blood flow and gas exchange, providing full cardiopulmonary bypass, but increases afterload.
Randomized trials of MCS devices remain challenging to conduct due to relative lack of equipoise on the part of treating physicians, leading to selective patient enrollment and limiting the generalizability of study results. The DanGer-Shock randomized 360 patients presenting with STEMI and cardiogenic shock of 24 hours duration to either microaxial flow pump or standard of care. The trial demonstrated a 26% reduction of all-cause mortality at 180 days (HR, 0.74 [95% CI, 0.55-0.99]; P = 0.04; absolute risk reduction, 12.7%; number needed to treat = 8) compared with standard of care. However, this came at the cost of increased risk of complications like bleeding, limb ischemia and renal replacement therapy in the microaxial flow pump group.
In light of this and other trial data, the guidelines give a Class 2a, LOE B recommendation for the use of a microaxial intravascular flow pump in patients with STEMI complicated by severe or refractory cardiogenic shock to reduce mortality. These patients should be noncomatose and have adequate peripheral vasculature to accommodate large-bore access.
Answer choice A is not correct as the use of VA-ECMO cannulation in this setting has been given a class 3 recommendation for lack of benefit. VA-ECMO has not been shown to reduce death compared with medical therapy alone in patients with cardiogenic shock in the setting of MI but increases major bleeding and vascular complications. In the absence of severe concomitant respiratory failure requiring oxygenation support, this strategy is not indicated in the patient described here. Further fluid resuscitation (answer choice C) is not likely to be helpful as right heart catheterization demonstrated elevated filling pressures. Placement of an intraaortic balloon pump (IABP) is not the next best step. The IABP-SHOCK II trial, which randomized patients with acute MI and severe cardiogenic shock to IABP or medical therapy showed no differences at 30 days or at long-term follow-up in the primary outcome of all-cause death. The use of IABP has a class 3 recommendation for lack of benefit in patients with cardiogenic shock secondary to acute myocardial infarction.
Main Takeaway
In selected patients with STEMI and severe or refractory cardiogenic shock, insertion of microaxial intravascular flow pump is reasonable to reduce death in a noncomatose patient with adequate vascular access.
Guideline Loc.
Section 8.2
16. AngioClub: A Nightmare in the Left Main: Atherectomy, Perforation, and Bailout
2026/10/19
CathMasters (Drs. Amit Goyal, Daniel Ambinder, and Nazli Okumus), with guests Drs. Mina Fares, Fariyal Cheema, and Jeremy Langrish discuss the management of an unprotected distal left main (LM) percutaneous coronary intervention (PCI) complicated by an Ellis grade III coronary perforation. An 88-year-old man presented with a non–ST-elevation myocardial infarction (NSTEMI), heavily calcified critical distal LM disease (culprit), and a chronic total occlusion (CTO) of the right coronary artery (RCA). The team walks through heart-team decision-making for palliative-intent LM PCI, the choice to forgo upfront mechanical circulatory support (MCS), rotational atherectomy and intravascular ultrasound (IVUS)–guided calcium modification, a provisional LM-to-left anterior descending (LAD) stent strategy, and the real-time, stepwise rescue of a large perforation — balloon tamponade, pericardiocentesis with autotransfusion, and a covered stent landed at the LAD ostium to spare the circumflex.
CathMasters is for educational purposes only.
CathMasters is for educational purposes only. Music by Elijah K from Pixabay
Media
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .ose-embedpress-responsive{
width: 600px!important;
height: 600px!important;
max-height: 600px!important;
}
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] iframe{
width: 600px!important;
height: 600px!important;
max-height: 600px!important;
}
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .embedpress-yt-subscribe iframe{
height: 100%!important;
}
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .ose-youtube > iframe{
height: 600px!important;
width: 600px!important;
max-width: 100%!important;
}
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .ose-youtube{
height: 600px!important;
width: 600px!important;
}
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .ose-giphy img{
height: 600px!important;
width: 600px!important;
}
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .ose-google-docs img{
height: 600px!important;
width: 600px!important;
}
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .ose-embedpress-responsive.ose-google-photos{
height: 100% !important;
max-height: 100% !important;
}
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .embera-embed-responsive-provider-gettyimages,
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .embera-embed-responsive-provider-gettyimages iframe,
[data-source-id="source-02f5e66f-a4cc-4e23-acb1-36934d7f8546"] .getty{
width: 600px!important;
height: 600px!important;
max-height: 600px!important;
max-width: 100%!important;
}
Pearls
“ST elevation in aVR” is a barometer of global distress, not a culprit locator. aVR ST elevation with diffuse ST depression signals left main/three-vessel disease or circumferential subendocardial supply–demand mismatch; only roughly 10–25% of such patients have an acute thrombotic occlusion. In this case, the changes resolved once pain/hemodynamics normalized.
After CHIP-BCIS3, mechanical support is a selective — not reflexive — decision. In complex high-risk PCI with ejection fraction ≤35%, routine elective left-ventricular unloading with a microaxial flow pump did not improve the composite outcome and showed a signal toward higher cardiovascular death. A hemodynamically stable patient with preserved EF, as here, generally does not warrant upfront support — and a 14-French femoral sheath carries real risk in a frail 88-year-old.
“The last 5% can guarantee you a 100% complication.” For a disease-free, favorably angulated circumflex ostium (Medina 1,1,0), the stepwise provisional single-stent LM-to-LAD strategy is the default and reduces target-lesion revascularization compared with upfront two-stent approaches. Define the procedural goal first — here, symptom relief, not survival — which justified leaving the RCA CTO untouched.
Ellis III perforation: tamponade buys time, the covered stent provides the definitive seal — and post-dilation is mandatory. Immediate balloon inflation at/across the perforation stabilizes the patient while the team mobilizes; a polytetrafluoroethylene/polyurethane covered stent seals large-vessel perforation, but residual “endoleak” around the stent is common and must be addressed with high-pressure post-dilation before reaching for a second stent.
In a left main bifurcation perforation, land the covered stent at the LAD ostium to spare the circumflex — and manage the bleed in parallel. Deliberately avoiding the distal LM/circumflex preserves flow and allows full wall apposition; keep an LM-sized covered stent on standby as bailout. Pericardiocentesis with autotransfusion (cell saver) is salvage therapy for hemorrhagic tamponade — heparinize each collection bag (10,000 units) so the perfusionist can re-infuse the patient’s own blood.
Notes
1. How should the high-risk ECG pattern of aVR ST elevation with diffuse ST depression be interpreted?
The pattern reflects a net ST vector toward aVR from widespread subendocardial injury; it is associated with left main or three-vessel disease and increased mortality, but has only ~10–14% positive predictive value for acute occlusive myocardial infarction.
Broad differential includes nonocclusive coronary disease and demand/supply mismatch (hypotension, sepsis, severe anemia, aortic stenosis) and repolarization abnormalities; resolution with pain relief or hemodynamic correction argues against acute occlusion.
In this NSTEMI presentation, the pattern correctly flagged critical distal LM disease as the culprit, confirmed angiographically.
2. How does the heart team frame revascularization in a frail elderly patient with complex disease?
The intent was explicitly palliative — symptom relief rather than prognostic gain — which removed the RCA CTO from consideration and focused treatment on the LM.
The patient was deemed a non-surgical candidate; after continued angina despite optimal medical therapy, the multidisciplinary team, patient, and family accepted PCI with a frankly stated 5–10% risk of a serious periprocedural complication.
Procedural planning emphasized “planning for success”: daytime timing, a full team brief, and preparation for complex PCI with calcium-modification algorithms available.
Shared-decision making with the patient and their family guided by their own goals is paramount in these complex cases.
3. When is mechanical circulatory support indicated for high-risk PCI?
CHIP-BCIS3 randomized 300 patients with complex disease and EF ≤35% to elective microaxial flow pump (Impella CP) versus standard care; routine unloading did not improve the hierarchical composite outcome and trended toward higher cardiovascular death.
A CHIP-BCIS3 hemodynamic substudy showed the pump reduced inotrope use but increased loss of pulse pressure and did not prevent myocardial stunning.
Randomized evidence does not support routine MCS outside cardiogenic shock; selection should weigh EF, baseline blood pressure, lesion predictability, and access risk. This patient — stable, normal biventricular function — had PCI without upfront support, with femoral access and bailout strategies kept in mind.
Enjoy CathMastes Ep 4 (Data to Delivery: CHIP-BCIS3 — Microaxial Flow Pump Support for High-Risk Complex PCI with Dr. Saraschandra Vallabhajosyula) to learn more about CHIP-BCIS3.
4. How is heavily calcified left main disease modified and assessed?
Left main atherectomy can be performed from the radial or femoral artery. Adequate support and appropriate guide selection are key. In this case, the setup was: right radial, 7.5-French sheathless guide for maximal support; workhorse wire and microcatheter exchanged for a dedicated 0.009-inch rotational wire; upfront rotational atherectomy chosen because the stenosis was too tight to safely balloon or image first.
Burr selection: aim for a burr-to-artery ratio of ~0.5–0.6; a relatively larger burr (here 1.75 mm) can be chosen when debulking nodular calcium rather than simply creating a channel. Note: the recording’s “no more than two-thirds” rule of thumb is more liberal than the published 0.5–0.6 ratio.
Technique: rotational speed ~160,000 rpm (within the safe 135,000–180,000 rpm range), short runs of 10–15 seconds (≤30 s) with a pecking motion and rest between runs, avoiding decelerations >5,000 rpm.
No-reflow prevention: continuous flush of heparinized saline with verapamil and nitroglycerin in the bag or vasodilators through the manifold between runs; left-sided atherectomy rarely needs temporary pacing, so pacing wires were abandoned for LM cases (a small atropine dose is used for large dominant RCA atherectomy instead). Aminophylline pre-treatment can also mitigate atherectomy-related bradyarrhythmias.
IVUS findings guided the plan: distal LM was the tightest concentric calcium with fractures at 2, 7, and 11 o’clock; os
15. ACS Guidelines Question #6 with Dr. Binita Shah
2026/09/23
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 4.4 of the 2025 ACS Guidelines.
The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by University of Miami cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Saahil Jumkhawala, and then by expert faculty Dr. Binita Shah.
Dr. Binita Shah is an associate professor of medicine, interventional cardiologist, Director for research in Interventional Cardiology, and Director of the Department of Medicine Clinical Investigator Track at NYU. She is also an associate director of interventional cardiology and director of the transcatheter valve program at the VA New York Harbor Healthcare System. She was a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
A 64-year-old male with a history of hypertension and dyslipidemia presents to the emergency department with crescendo angina. His ECG shows ST-segment depression in leads V4–V6, and high-sensitivity troponin levels are significantly elevated. A diagnosis of NSTE-ACS is made, and the patient is scheduled for an early invasive strategy with percutaneous coronary intervention (PCI). Which of the following parenteral anticoagulants is NOT recommended for use as a standalone agent during the PCI procedure itself?
A
Fondaparinux
B
Bivalirudin
C
Unfractionated Heparin
D
Enoxaparin
Explanation
The correct answer is A. The choice of parenteral anticoagulation for a patient with Non-ST-Elevation Acute Coronary Syndrome (NSTE-ACS) undergoing Percutaneous Coronary Intervention (PCI) is governed by both efficacy in preventing ischemic events and the safety profile regarding bleeding.The following are the recommended Agents for PCI:
Unfractionated Heparin (UFH): In patients with NSTE-ACS, intravenous unfractionated heparin (UFH) is useful to reduce ischemic events (Class 1, LOE C-EO).
Bivalirudin: This direct thrombin inhibitor is recommended as an alternative to UFH. In patients with NSTE-ACS undergoing PCI, bivalirudin may be reasonable as an alternative to UFH to reduce bleeding and mortality (Class 2b, LOE B-R)
Enoxaparin: In patients with ACS, intravenous enoxaparin may be considered as an alternative to UFH at the time of PCI to reduce ischemic events (Class 2B, LOE B)
In patients with ACS, fondaparinux should not be used to support PCI because of the risk of catheter thrombosis (Class 3: Harm; LOE B-R). The primary reason is due to the risk of catheter thrombosis. Large-scale trials (notably the OASIS-5 trial) demonstrated that using fondaparinux alone during PCI led to a significantly higher rate of thrombus formation on the diagnostic and therapeutic catheters. In the OASIS-5 trial, an increase was observed in the rate of catheter-related thrombus with fondaparinux compared with enoxaparin (0.9% versus 0.4%). Similar results were observed in the OASIS-6 trial, in which a higher rate of guiding-catheter thrombosis and more coronary complications with fondaparinux were observed when used during PCI.
Main Takeaway
– Parenteral anticoagulation for a patient with Non-ST-Elevation Acute Coronary Syndrome (NSTE-ACS) undergoing Percutaneous Coronary Intervention (PCI) is governed by both efficacy in preventing ischemic events and the safety profile regarding bleeding.
Expert Suggestions
When to consider AC other than UFH prior to and during PCI.Considerations around patients with HIT.
Guideline Loc.
Section 4.4
14. ACS Guidelines Question #5 with Dr. Binita Shah
2026/09/19
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 4.3 of the 2025 ACS Guidelines.
The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by Cleveland Clinic interventional and structural cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Eunice Dugan, and then by expert faculty Dr. Binita Shah.
Dr. Binita Shah is an associate professor of medicine, interventional cardiologist, Director for research in Interventional Cardiology, and Director of the Department of Medicine Clinical Investigator Track at NYU. She is also an associate director of interventional cardiology and director of the transcatheter valve program at the VA New York Harbor Healthcare System. She was a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
A 64-year-old woman with NSTE-ACS is taken to the cardiac catheterization laboratory. She is P2Y12 inhibitor-naive as she was unable to tolerate oral intake due to severe nausea and vomiting. Coronary angiography reveals a high-grade, thrombotic lesion in the mid-Right Coronary Artery. The interventionalist decides to initiate an intravenous P2Y12 inhibitor before proceeding with PCI. Which of the following is the most appropriate management strategy?
A
Administer Cangrelor as a 30 mcg/kg IV bolus followed by a 4 mcg/kg/min infusion for at least 2 hours or the duration of PCI, whichever is longer.
B
Administer Eptifibatide (GP IIb/IIIa inhibitor) as a routine double-bolus followed by an infusion to replace the need for P2Y12 inhibition.
C
Delay the procedure for 2 hours to allow for the administration and absorption of 600 mg of oral Clopidogrel.
D
Administer Cangrelor as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion for exactly 1 hour.
Explanation
The correct answer is A.
Cangrelor is the only intravenous P2Y12 inhibitor currently available. It is a direct-acting, intravenous antagonist of the P2Y12 receptor characterized by rapid and potent platelet inhibitory effects, with restoration of platelet function occurring within 1 hour of drug discontinuation. It also has a very short half-life (3–6 minutes).Among patients with ACS undergoing PCI who have not received a P2Y12 inhibitor, intravenous cangrelor may be reasonable to reduce periprocedural ischemic events (Class 2B; LOE B-R).
Dosing Strategy:Bolus: 30mcg/kg IV bolus administered rapidly (under 1 minute) before PCI begins.Infusion: 4 mcg/kg/min IV infusion.Duration: The infusion must run for at least 2 hours or for the duration of the PCI, whichever is longer.
Transition to Oral Therapy:Ticagrelor: 180mg can be given at any time (during or after the infusion).Prasugrel/Clopidogrel: loading dose must be given immediately after the infusion is stopped. Giving these earlier can lead to a drug-drug interaction where the Cangrelor prevents the active metabolite from binding to the receptor.
In the CHAMPION PHOENIX trial, cangrelor was studied versus clopidogrel in patients undergoing PCI for acute or stable coronary syndromes. Cangrelor was administered as an intravenous bolus prior to PCI followed by an infusion for at least 2 hours or for the duration of the procedure, whichever was longer. In the control arm, clopidogrel was administered as a 600- or 300-mg loading dose immediately before or after PCI. At 48 hours, the primary endpoint of all- cause death, MI, ischemia-driven revascularization, or stent thrombosis was significantly reduced with cangrelor, with similar effects observed among those presenting with NSTE-ACS or STEMI.
Glycoprotein IIb/IIIa receptor inhibitors are parenterally administered drugs that block platelet aggregation by preventing platelet cross-linking via fibrinogen or von Willebrand factor binding to the glycoprotein IIb/IIIa receptor. Routine administration of GP IIb/IIIa inhibitors before PCI is not recommended and is associated with increased bleeding without improving ischemic outcomes. (Class 3 – No Benefit). Incurrent practice, the role of glycoprotein IIb/IIIa receptor inhibitors is largely limited to adjunctive use at the time of PCI in patients with large thrombus burden or as“rescue” or “bailout” therapy in patients with PCI complications such as no-reflow or persistent or recurring thrombus at the lesion.
B is incorrect. Routine “upstream” or periprocedural use of GP IIb/IIIa inhibitors (GPI) is Class 3 (No Benefit) for most patients. Large trials (like EARLY-ACS) showed that routine GPI use significantly increases major bleeding without a proportional decrease in ischemic events compared to modern P2Y12 inhibitors.
C is incorrect. In patients with NSTE-ACS or STEMI who are already in the lab, delaying the procedure to wait for oral drug absorption is not recommended.
D is incorrect. The correct bolus is 30mcg/kg. Cangrelor must be infused for at least 2 hours or the duration of the PCI, whichever is longer. Stopping at 1 hour would leave a “gap” in platelet inhibition before an oral agent can take effect. Because Cangrelor’s half-life is only 3–6 minutes, a premature stop increases the risk of acute stent thrombosis.
Main Takeaway
Cangrelor may be reasonable among patients with ACS undergoing PCI who have not received a P2Y12 inhibitor to reduce periprocedural ischemic events (Class 2b, LOE B-R).
Guideline Loc.
Section 4.3.3-4.3.4
13. ACS Guidelines Question #4 with Dr. Binita Shah
2026/09/18
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Sections 4.3.2 and 4.4 of the 2025 ACS Guidelines.
The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by University of Miami cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Saahil Jumkhawala, and then by expert faculty Dr. Binita Shah.
Dr. Binita Shah is an associate professor of medicine, interventional cardiologist, Director for research in Interventional Cardiology, and Director of the Department of Medicine Clinical Investigator Track at NYU. She is also an associate director of interventional cardiology and director of the transcatheter valve program at the VA New York Harbor Healthcare System. She was a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
Q4- Oral P2Y12 Inhibitors during Hospitalization (4.3.2) and Parenteral Anticoagulation (4.4 9)
A 78-year-old man with a history of hypertension and controlled type 2 diabetes presents to a rural emergency department with 90 minutes of persistent, crushing, substernal chest pain. His ECG reveals 3-mm STE in leads V1 through V4. The nearest PCI-capable center is approximately 140 minutes away by ground transport, and air transport is unavailable due to weather. The patient refuses transfer to another facility for the duration of this admission. The clinical team decides to proceed with fibrinolytic therapy using weight-based Tenecteplase (TNK). Which of the following is the most appropriate initial antithrombotic regimen to accompany the fibrinolytic agent?
A
Clopidogrel 300 mg loading dose; Enoxaparin 30 mg IV bolus followed by 1.0 mg/kg SC every 12 hours.
B
Clopidogrel 75 mg (no loading dose); Enoxaparin 0.75 mg/kg SC every 12 hours (no IV bolus).
C
Ticagrelor 180 mg loading dose; Unfractionated heparin (UFH) weight-based IV bolus and infusion.
D
Prasugrel 10mg (no loading dose); Fondaparinux 2.5 mg IV bolus followed by 2.5 mg SC daily.
Explanation
The correct answer is B.
Clopidogrel is the only P2Y12 inhibitor with a Class 1 recommendation for use alongside fibrinolytic therapy to reduce death and MACE (Class 1, LOE A). Of note, pharmacodynamic variability in response to clopidogrel has been well described, and hyporesponders may be at increased risk of MACE and stent thrombosis when treated with clopidogrel after PCI. Other P2Y12 inhibitors such as ticagrelor and prasugrel are more potent than clopidogrel and achieve more rapid onset of inhibition of platelet activation but with increased risk of bleeding compared with clopidogrel.
When administered concurrently with fibrinolytic as the reperfusion strategy, clopidogrel is recommended to be administered with a loading dose (300 mg, then 75 mg daily) for patients 24 hours after a fibrinolytic agent) are alternatives to support PCI.
Parenteral anticoagulation is recommended for all patients with ACS, irrespective of the initial treatment strategy, to treat the underlying pathophysiologic process (coronary atherothrombosis) and reduce the risk of recurrent MACE. The choice of a parenteral anticoagulant can be complex because it is influenced by various factors, including vascular access site, renal function, and concomitant use of other antiplatelet or anticoagulant agents. In patients with STEMI treated with fibrinolytictherapy, parenteral anticoagulation is recommended before and after fibrinolytic therapy to reduce ischemic events.
In patients with STEMI who received fibrinolytic therapy and who are not planned for an invasive approach (as with the patient in the question stem), enoxaparin is the preferred anticoagulant over UFH. In the ExTRACT-TIMI 25 study, enoxaparin until hospital discharge or for a maximum of 8 days (whichever came first) was compared with UFH administered for at least 48 hours. The primary endpoint of death or nonfatal recurrent MI through 30 days occurred in 12% in the UFH group compared with 9.9% in the enoxaparin group. In a meta-analysis of 14 randomized trials, UFH did not reduce reinfarction or death in patients treated with fibrinolytic therapy. In contrast, low-molecular- weight heparin reduced the risk of reinfarction and death compared with placebo and the risk of reinfarction.
In patients >75 years of age, the dosing must be modified: Omit the initial 30 mg IV bolus. Reduce the subcutaneous dose to 0.75 mg/kg (instead of the standard 1.0 mg/kg). The first two SC doses should also be capped at a maximum of 75 mg each.
After receiving the fibrinolytic and adjusted antithrombotics, the patient should be transferred to a PCI center to facilitate immediate or early catheterization depending on the clinical circumstances, if this is in-line with the patient’s wishes. Hospitals should have transfer protocols in place to allow for a seamless transfer to the PCI-capable facility as soon as it is safe to do so. A detailed assessment of clinical status is critical to determine the timing of angiography.
A is incorrect: This is the standard dose for patients under 75 years of age. In a 78-year-old, the IV bolus of Enoxaparin and the Clopidogrel load significantly increase the risk of a fatal brain bleed.
B is incorrect: Ticagrelor is not recommended as an adjunct to fibrinolysis in the 2025 ACS guidelines.
D is incorrect: While fondaparinux may be used alongside lytic therapy when not planning an invasive strategy, prasugrel does not have a Class 1 recommendation for use with fibrinolytic therapy.
Main Takeaway
– Clopidogrel is the only P2Y12 inhibitor with a Class 1 recommendation for use alongside fibrinolytic therapy
Guideline Loc.
Sections 4.3.2 and 4.4 Table 10
12. ACS Guidelines Question #3 with Dr. Binita Shah
2026/09/18
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 3.2 of the 2025 ACS Guidelines.
The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by Cleveland Clinic interventional and structural cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Eunice Dugan, and then by expert faculty Dr. Binita Shah.
Dr. Binita Shah is an associate professor of medicine, interventional cardiologist, Director for research in Interventional Cardiology, and Director of the Department of Medicine Clinical Investigator Track at NYU. She is also an associate director of interventional cardiology and director of the transcatheter valve program at the VA New York Harbor Healthcare System. She was a member of the 2025 ACS Guidelines writing committee.
Question
Answer
QuestionAnswer
A 55-year-old woman is brought to the Emergency Department after an out-of-hospital cardiac arrest. She had a witnessed collapse with an initial shockable rhythm. Return of Spontaneous Circulation (ROSC) was achieved after 15 minutes of Advanced Cardiac Life Support (ACLS). Her post-resuscitation ECG shows diffuse ST-segment depression but no ST-segment elevation. She remains comatose.
Which of the following is the most appropriate next step in her management regarding coronary angiography?
A
Immediate emergency coronary angiography (within 2 hours) should be performed.
B
Routine emergency coronary angiography is not recommended in the absence of ST-segment elevation or hemodynamic instability.
C
Coronary angiography should be delayed for at least 72 hours to allow for neurological recovery.
D
Fibrinolytic therapy should be administered immediately if the patient cannot reach a cath lab within 90 minutes.
Explanation
The correct answer is B.In resuscitated patients who are comatose after cardiac arrest, electrically and hemodynamically stable, and without evidence of STEMI, immediate angiography is not recommended due to lack of benefit (Class 3: No Benefit; LOE A)Patients who have been resuscitated after cardiac arrest and are noncomatose or who are comatose with favorable prognostic features and with evidence of STEMI, should undergo PPCI to improve survival. (Class 1; LOE B-NR).For patients such as this one, a delayed or selective approach should be taken once the patient is stabilized. Early angiography should not be denied solely based on a comatose state, but it should be deferred if there are clear non-cardiac causes for the arrest or if the patient’s overall prognosis is futile.A is incorrect because recent evidence shows no benefit to “emergency” PPCI for stable patients without ST-elevation.C is incorrect because while we wait for stability, we don’t necessarily have a fixed 72-hour “mandatory” delay for the heart if ischemia is suspected.D is incorrect, as fibrinolysis is generally not indicated for post-arrest patients without clear STEMI and carries risks in a post-CPR setting due to potential trauma.The MIRACLE2 Score is a tool for neuroprognostication. It helps clinicians estimate the likelihood of a poor neurological outcome at 6 months. A high score suggests that the benefit of an invasive procedure may be outweighed by the severity of the brain injury.Components of MIRACLE2:M – Missed (unwitnessed) arrest
I – Initial non-shockable rhythm
R – Reactive pupils at ROSC
A – Age (points increase significantly at >60 and >80)
C – Rhythm change (e.g., VF to PEA)
L – Low pH (pH 5 indicates a high risk of poor neurological recovery, which may lead a Heart Team to favor stabilization over immediate emergency angiography in patients without ST-elevation.Early recognition of STEMI in resuscitated patients and direct transfer to a PCI-capable center is associated with improved survival. Survival-to-hospital discharge in the patient who is comatose with out-of-hospital cardiac arrest is 10% regardless of etiology. Those with a witnessed arrest and a shockable rhythm have improved survival. Outcomes for patients with STEMI who are awake after resuscitated cardiac arrest are comparable to patients with STEMI who were not in cardiac arrest. For this reason, patients with cardiac arrest who have achieved return of spontaneous circulation (ROSC) and are awake with STEMI on ECG are candidates for PPCI. However, care should be individualized in the comatose patient with rapid assessment of the patient’s clinical features and cardiac arrest characteristics before proceeding with invasive angiography. In contrast, patients who are stable without ST-segment elevation after out-of-hospital cardiac arrest do not require immediate coronary angiography. Coronary angiography in this setting can be deferred pending further risk stratification.
Main Takeaway
Patients with cardiac arrest and STEMI who have been resuscitated should preferentially be transferred by EMS to a PPCI-capable center. Certain prognostic scores can help risk stratify patients prior to catheterization.
Guideline Loc.
Section 3.2. Management of Patients Presenting With Cardiac Arrest
11. AngioClub: TAVR in the Bicuspid Aortic Valve
2026/08/21
In this AngioClub-style episode from the CardioNerds CathMasters, Drs. Amit Goyal, Nazli Okumus, Niko Spilias, and Grant Reed discuss transcatheter aortic valve replacement (TAVR) in bicuspid aortic valve (BAV) stenosis. Through a case of a 71-year-old man with severe aortic stenosis (AS), reduced left ventricular ejection fraction (LVEF), a recent heart failure hospitalization, and a heavily calcified Sievers type 1 BAV, the panel works through TAVR versus surgical aortic valve replacement (SAVR) selection, lifetime management, anatomic and procedural risk (paravalvular leak [PVL], permanent pacemaker [PPM], stroke, annular rupture), balloon/valve sizing, cerebral embolic protection (CEP), and expected LVEF recovery. The episode highlights that BAV is not itself a contraindication to TAVR but demands meticulous CT-based planning and phenotype-specific risk stratification.
CathMasters is for educational purposes only.
CathMasters is for educational purposes only. Music by Elijah K from Pixabay
Media
Pearls
BAV was excluded from the pivotal TAVR randomized trials — every comparison of TAVR vs SAVR in bicuspid anatomy comes from registries and observational cohorts, so shared decision-making and Heart Team review are essential.
"The more tricuspid-like the bicuspid valve behaves, the more predictable the TAVR." Symmetric calcification and absence of a heavily calcified raphe/LVOT favor good outcomes.
The highest-risk BAV phenotype is a calcified raphe plus excess leaflet calcification — this combination tracks with roughly 3-fold higher 2-year mortality (~25.7%) and more aortic root injury and PVL; in general, avoid TAVR in these patients unless surgical risk is prohibitive.
"Perfection is the enemy of the good." Accept mild PVL rather than aggressively post-dilating against a rock-hard calcified annulus, where chasing perfection risks annular rupture.
A high mean gradient despite a low LVEF signals afterload-mediated dysfunction with reserve — these ventricles often recover after TAVR; about one-third of low-EF patients show early LVEF improvement, and very-low-EF/low-flow cohorts recover even more.
Notes
When is TAVR reasonable instead of SAVR in a bicuspid valve?
SAVR remains first-line for truly young, low-risk BAV patients, particularly those 80.
Registry and meta-analytic data show comparable short-term mortality but signals for higher stroke, PPM, PVL, and inferior long-term survival with TAVR vs SAVR in BAV; NOTION-2 showed a non-significant higher event rate with TAVR in the bicuspid subgroup (20.4% vs 7.8%).
The case patient's low STS score (1.6%) underestimates true risk given severe mobility limitation, non-ischemic-appearing LV dysfunction, and a recent decompensated heart failure admission — factors not captured by STS-PROM that justified favoring TAVR after Heart Team discussion.
How does lifetime management inform the index procedure?
Lifetime management aims to minimize the number of sternotomies and to sequence interventions (redo-TAVR, valve-in-valve, TAVR explant/SAVR) optimally over a patient's remaining lifespan.
Guidelines favor SAVR in patients 10,000 AU) plus internal carotid stenosis raises embolic concern.
How should the balloon and valve be sized in bicuspid anatomy?
Predilation goals are crossability and, more importantly, circular, well-expanded valve deployment within the limits of the calcium; adequate expansion of a properly sized valve is increasingly linked to reduced HALT, lower gradients, and durability.
For heavily calcified BAV, size the balloon conservatively — often to the minimum annular diameter and adjusted down further for focal annular calcium — with a low threshold to post-dilate for expansion (not to chase trivial PVL).
Balloon-expandable valves apply more radial force and expand calcified annuli more reliably; self-expanding platforms rely more on adequate predilation and are now sized/predilated to the average diameter per contemporary guidance.
Beyond the virtual basal ring, assess for root tapering and intercommissural distance a few millimeters above the annulus; downsize if the supra-annular root is restrictive to avoid root injury.
When should cerebral embolic protection be used?
The randomized PROTECTED TAVR trial found no statistically significant reduction in periprocedural stroke with CEP (2.3% vs 2.9%), though the confidence interval did not exclude benefit and disabling stroke was numerically lower (0.5% vs 1.3%).
Meta-analyses conflict: pooled randomized data (including PROTECTED TAVR and BHF PROTECT-TAVI) suggest no significant stroke reduction, whereas some analyses incorporating observational data report lower stroke.
Given the absence of a clear randomized benefit, use is individualized; a heavily calcified BAV with a very high calcium score, carotid disease, and planned predilation is a reasonable selective indication, though data does not strongly support this practice.
What LVEF recovery can be expected after TAVR in low-EF AS?
A high mean gradient (42 mm Hg here) despite LVEF 30–35% indicates predominantly afterload-mediated dysfunction with likely contractile reserve and favorable recovery potential.
Roughly one-third of high-/intermediate-risk patients with baseline LVEF 50% have early (≥10-point) LVEF improvement; low-flow/low-gradient patients with LVEF 30% show even larger absolute gains and outcomes independent of dobutamine contractile reserve.
Prior myocardial infarction, diabetes, coronary artery disease, and PPM are associated with reduced likelihood of LVEF recovery.
Case outcome mirrors this: LVEF rose to 40–45% by the next day and 55–60% at one month, with a mean gradient of 12 mm Hg, DVI 0.42, and only trace PVL.
References
Makkar RR, Yoon SH, Chakravarty T, et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke among patients at low surgical risk. JAMA. 2021;326(11):1034-1044. PubMed
Yoon SH, Kim WK, Dhoble A, et al. Bicuspid aortic valve morphology and outcomes after transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76(9):1018-1030. PubMed
Kapadia SR, Makkar R, Leon M, et al. Cerebral embolic protection during transcatheter aortic-valve replacement (PROTECTED TAVR). N Engl J Med. 2022;387(14):1253-1263. PubMed
Praz F, Borger MA, Lanz J, et al. 2025 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2025. PubMed
Jørgensen TH, Savontaus M, Willemen Y, et al. Three-year follow-up of the NOTION-2 trial: TAVR versus SAVR to treat younger low-risk patients with tricuspid or bicuspid aortic stenosis. Circulation. 2025. PubMed
Nagasaka T, Patel V, Shechter A, et al. Impact of balloon-expandable TAVR valve deformation and calcium distribution on outcomes in bicuspid aortic valve. JACC Cardiovasc Interv. 2024;17(17):2026-2038. PubMed
Baman JR, Medhekar AN, Malaisrie SC, et al. Management challenges in patients younger than 65 years with severe aortic valve disease: a review. JAMA Cardiol. 2023;8(3):281-289. PubMed
Liu J, Wei D, Wu Q, et al. Comparison of short- and long-term outcomes between transcatheter and surgical aortic valve replacement for bicuspid aortic valve stenosis: a systematic review and meta-analysis. Int J Surg. 2025. PubMed
Mehaffey JH, Jagadeesan V, Kawsara M, et al. Transcatheter vs surgical aortic valve replacement in bicuspid aortic valves. Ann Thorac Surg. 2025. PubMed
Beerkens FJ, Tang GHL, Kini AS, et al. Transcatheter aortic valve replacement beyond severe aortic stenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2025;85(9):944-964. PubMed
Gupta T, Malaisrie SC, Batchelor W, et al. Decision-making approach to the treatment of young and low-risk patients with aortic stenosis. JACC Cardiovasc Interv. 2024;17(21):2455-2471. PubMed
Praz F, Beyersdorf F, Haugaa K, Prendergast B. Valvular heart disease: from mechanisms to management. Lancet. 2024;403(10436):1576-1589. PubMed
Kolte D, Bhardwaj B, Lu M, et al. Association between early left ventricular ejection fraction improvement after transcatheter aortic valve replacement and 5-year clinical outcomes. JAMA Cardiol. 2022;7(9):934-944. PubMed
Maes F, Lerakis S, Barbosa Ribeiro H, et al....
10. Crisis Control: Bailout Management for Failed Percutaneous Axillary Artery Closure with Dr. Rajiv Tayal
2026/08/02
CathMasters hosts Dr. Amit Goyal, Dr. Li Pang, and Dr. Nazli Okumus discuss bailout management for failed percutaneous axillary artery closure with expert Dr. Raj Tayal. Building on the Data-to-Delivery and Proctor Playbook episodes, this Crisis Control episode walks through a scenario of wide-open extravasation after Perclose failure during right axillary access TAVR. The team covers a stepwise escalation algorithm — from repeat Perclose deployment and serial balloon tamponade with protamine reversal, to hybrid closure with AngioSeal, to covered stent placement with the Viabahn endoprosthesis — and discusses when to call vascular surgery. This episode translates the 2022 SCAI Position Statement bailout recommendations into a practical, cath-lab-ready crisis management framework.
CathMasters is for educational purposes only.
CathMasters is for educational purposes only. Music by Elijah K from Pixabay
Pearls
As long as wire access is maintained across the arteriotomy, the operator retains full bailout capability — the working wire going through the arteriotomy allows for repeat vascular closure device attempt, including Perclose and/or AngioSeal (hybrid closure), while the safety wire positioned in the axillary artery from the secondary access allows for balloon tamponade and/or covered stent deployment. Losing wire access is the true crisis.
If both Perclose sutures fail (snapped or cut), the "post-closure" rescue technique involves reinserting a large sheath, placing two 0.035″ wires side-by-side, removing the sheath, then inserting two 8F sheaths side-by-side for sequential Perclose deployment — maintaining wire access through the second sheath throughout.
A 6Fr sheath will accommodate 5-7 mm Viabahn covered stents while a 7Fr sheath will accommodate up to a 9mm Viabahn covered stent.
When deploying a covered stent from the radial artery without a destination sheath, use vascular markers on the screen to mark the bleeding site, lock the table position, and deploy based on those landmarks — retrograde contrast injection from the radial opacifies the vessel poorly compared to antegrade femoral injection.
Covered stent placement in the 2nd segment of the axillary artery has minimal long-term sequelae — there are no critical branches that, if covered, would cause significant ischemia. Covering the lateral thoracic artery is acceptable; the subscapular artery is less desirable but tolerable. Avoid occluding the suprascapular artery (1st segment).
Notes
1. Initial Assessment: Extravasation After Perclose Failure
Bleeding is the most common complication of transaxillary access. Risk increases with larger sheaths, patient age, longer dwell time, tortuosity, urgency, and anticoagulation status. Hemostasis failure can lead to bleeding into the axillary space with possible brachial plexus compression and permanent nerve injury. As the axillary artery is extrathoracic, hemothorax should not occur if vessel puncture was in the correct location.
The critical first question after failed closure: do you still have wire access through the arteriotomy and a safety wire in the artery? If yes, the full spectrum of bailout options remains available.
2. Stepwise Escalation Algorithm for Failed Closure
The following algorithm represents a synthesis of the SCAI Position Statement recommendations and Dr. Tayal's practical approach:
Step 1 — Repeat Perclose: If one suture snapped but wire access is maintained, deploy an additional Perclose. This maintains wire access and allows interval assessment. If improvement is seen, proceed with observation.
Step 2 — Serial balloon tamponade: Advance the tamponade balloon to the arteriotomy site (not proximal to it), inflate at 4–6 atm with simultaneous external manual compression × 5 minutes → deflate → angiogram. Repeat for a second 5-minute cycle if needed.
Step 3 — Protamine reversal + balloon tamponade: Administer protamine, then repeat balloon tamponade × 5 minutes with external pressure. Thrombosis risk from protamine in an 8–10 mm axillary artery is low compared to coronary-sized vessels.
Step 4 — Hybrid closure (AngioSeal): If bleeding is minimal and appears to be tract oozing between sutures, deploy an AngioSeal collagen plug. Although this sacrifices wire access through the axillary arteriotomy, the 0.018″ safety wire from the secondary femoral/radial access provides continued bailout capability.
Step 5 — Covered stent: If bleeding persists after multiple tamponade cycles, proceed to covered stent deployment (see below).
Step 6 — Surgical repair: Reserved for scenarios where covered stent is not feasible or effective (see below).
3. Post-Closure Rescue Technique (Both Percloses Failed)
If both sutures are lost (snapped, cut, or pulled through), reinsert a large sheath (12–14F) to tamponade the arteriotomy.
Place two 0.035″ wires through the sheath.
Remove the sheath with both wires in place.
Insert two 8F sheaths side-by-side, one over each wire.
Deploy Perclose sequentially through one sheath while maintaining wire access through the other.
If post-closure Perclose also fails, pivot to AngioSeal or covered stent via the second sheath.
4. Covered Stent Selection and Deployment
Viabahn (W. L. Gore & Associates, Inc.) is the preferred covered stent for axillary artery bailout due to superior apposition and crush resistance in this mobile location. Self-expanding covered stents conform to the artery's shape and adapt to the dynamic environment of the shoulder.
Sizing: oversize by ≥1 mm relative to the artery diameter. For most patients (average axillary artery 6–6.5 mm), a 7 or 8 mm Viabahn covers the majority of cases. A 9 mm is rarely needed.
Sheath compatibility: Viabahn 5–8 mm requires a 6–7F delivery system.
Delivery route:
Radial artery: A standard 6–7F slender sheath accommodates Viabahn up to 8 mm. However, visualization is limited (retrograde injection opacifies poorly). Use vascular markers on the screen to mark the bleeding site, lock the table, and deploy based on landmarks. The SCAI Position Statement recommends a long sheath from the radial approach, as passage of balloons and stents can induce spasm and entrapment.
Femoral artery: Preferred for the first 5–10 cases — allows antegrade contrast injection with superior visualization and accommodates larger sheaths/devices. A 7–8F long (90–110 cm) sheath is recommended.
Brachial artery: Avoid if possible; reserve for cases requiring stent sizes >8 mm when femoral access is unavailable.
Length: Use a 50 mm stent and err on the side of extra length. Attempting to be too precise with a short stent risks needing additional stents proximally or distally.
Post-dilation: Avoid if possible — post-dilating a self-expanding stent beyond its intended diameter causes foreshortening. Oversizing at initial deployment is preferable.
Branch vessel considerations: In the 2nd segment, covering the lateral thoracic artery is acceptable. The subscapular artery (3rd segment) is less desirable to cover. The suprascapular artery (1st segment) should not be occluded. The vertebral and internal mammary arteries (subclavian) must be avoided, but these are normally far proximal from the access site in the 2nd axillary artery segment.
Long-term outcomes: Covered stents in the axillary artery are well-tolerated with minimal long-term sequelae. The PAXA Registry reported secondary closure success in 98% of patients after adjunctive endovascular procedures (including 37 covered stents), with 100% axillary artery patency on follow-up CTA in the Al Adas et al. series.
5. When Covered Stent Is Not Feasible or Effective — Surgical Bailout
Covered stent may be infeasible when: (1) the delivery system cannot be advanced (severe tortuosity, spasm), (2) the injury is too proximal (1st segment near the thoracic outlet), or (3) a mechanical complication prevents device extraction (e.g., partially deployed balloon-expandable TAVR valve trapped in the artery as referenced in the podcast episode).
In the case described by Dr. Tayal, a balloon-expandable TAVR valve balloon ruptured on annular calcium, leaving a partially inflated valve that could not be fully deployed or withdrawn. The team pulled the device back into the axillary artery, inflated a proximal balloon to control bleeding, and a vascular surgeon performed a cutdown, extracted the device, placed a conduit, and the TAVR was completed successfully through the same artery.
Key principle: if the arteriotomy is in the 2nd segment, proximal vascular control can be achieved endovascularly (balloon tamponade), buying time for surgical involvement without catastrophic hemorrhage.
Direct surgical repair is preferable in some cases to avoid the risks of stent grafts (side branch occlusion, restenosis, thrombosis, infection, reduced mobility). In most cases, the arteriotomy can be repaired primarily unless there is significant atherosclerotic disease or vessel wall disruption, in which case patch angioplasty or interposition graft may be required.
6. Proactive Measures to Minimize Crisis
Notify vascular surgery before the procedure — share the plan, data, and bailout strategy. Collegial pre-procedural communication prevents adversarial dynamics if complications arise.
Have Viabahn stents (7 mm and 8 mm) in the room, not in a remote storage location.
Experienced operators should achieve a 2–3% failure rate requiring covered stent or surgical conversion. The PAXA Registry reported a 1.5% open conversion rate, and the Al Adas et al. series reported a 6.9% covered stent rate (trending down to 4% in the late cohort with experience).
Vascular complications from percutaneous transaxillary access, while reported at higher rates than transfemoral (up to 17% major vascular), do not appear to influenc
9. Proctor Playbook: Percutaneous Transaxillary Access and Closure: State-of-the-Art Technique with Dr. Rajiv Tayal
2026/07/10
CathMasters Drs. Amit Goyal, Li Pang, and Dr. Nazli Okumus, discuss state-of-the-art percutaneous axillary arterial access and closure with expert proctor Dr. Raj Tayal. Using a simulated case of Impella-supported high-risk PCI in a patient with severe bilateral iliofemoral PAD, the team walks through a step-by-step proctor playbook: pre-procedural CTA planning, laterality selection, room and arm setup, axillary artery anatomy, ultrasound-guided access technique, safety wire strategy, pre-closure with suture-mediated vascular closure devices, dry closure with balloon tamponade, and a bailout algorithm for failed hemostasis. This episode translates the 2022 SCAI Position Statement on Best Practices for Percutaneous Axillary Arterial Access into actionable, cath-lab-ready technique.
Episode 8 reviews the evidence base for this technique in the “Data-to-Delivery” discussion and Episode 10 will tackle vascular complication management with transaxillary access in the “Crisis Control” discussion.
CathMasters is for educational purposes only.
CathMasters is for educational purposes only. Music by Elijah K from Pixabay
Pearls
Target the second segment of the axillary artery (posterior to pectoralis minor) — it is extrathoracic, has no critical branches in its course, is compressible against the chest wall, and carries the lowest risk of brachial plexus injury because no cord passes anterior to it.
Arm abduction to 90° lengthens the second segment, brings the artery more superficially, and allows the operator to remain parallel to the vessel — reducing the tendency to splay the artery and cause occult bleeding beneath the pectoralis muscle.
The axillary artery has a thicker elastic lamina and a thinner muscular lamina than the femoral artery, making it more susceptible to "pull-through" injury with excessive VCD suture tension. Dr. Tayal recommends placing the Perclose sutures at 11-and-1 o'clock (or parallel with both at 12 o'clock) rather than the traditional 10-and-2 o'clock to reduce the risk of iatrogenic stenosis.
Use an 0.018″ safety wire (not 0.014″) — it provides sufficient support to deliver a Viabahn-covered stent if needed, and during dry closure, a 0.035″ balloon can be advanced over it, allowing a completion angiogram through a Tuohy-Borst valve without removing the wire.
Dry closure bailout algorithm: inflate → 5 min hold with external pressure → deflate and angiogram → repeat if needed → give protamine and repeat → if still bleeding, proceed to covered stent or hybrid closure (AngioSeal). Always have Viabahn stents in the room, not elsewhere!
Notes
1. Pre-Procedural Planning: CTA Checklist and Screening
CTA is the gold standard for pre-procedural planning. Key assessments include: minimum luminal diameter (generally≥6 mm), calcification burden and distribution, tortuosity, aneurysmal disease, and relationship to branches (vertebral artery, IMA, lateral thoracic, subscapular).
Per the SCAI Position Statement, absolute contraindications include a prior covered stent or surgical repair that renders the artery unsuitable for percutaneous access. Relative contraindications include vessel calcification, stenosis, tortuosity, aneurysmal dilatation, or prior dissection.
When CTA is unavailable (e.g., AKI, emergent cases), ultrasound assessment of the axillary artery, with or without angiography, via an ipsilateral radial or femoral approach using a JR4 or 3DRC catheter, is a reasonable alternative. The axillary artery is infrequently affected by atherosclerosis (~2%), with disease most commonly located at the subclavian ostium.
Note: CT scans are typically performed with the arms above the head, which can make vessels appear more tortuous or foreshortened than they are when the arms are abducted to 90° during the procedure.
2. Laterality Selection: Left vs. Right
Left axillary access is generally preferred for TAVR due to more favorable delivery angles to the aortic valve (especially in older patients with type II/III aortic arches), avoidance of the brachiocephalic artery, and preservation of the innominate artery for cerebral embolic protection if needed.
Right axillary access offers a simpler room setup (no need to flip screens or add a prep table) and may be reasonable in younger patients (type I arch) or for specific TAVR valve alignments.
Stroke risk with transaxillary access is consistently elevated (~6–8%) regardless of laterality, valve type, or surgical vs. percutaneous approach. The Hostile Registry reported right-sided stroke rates nearly double those of left-sided (6.3% vs. 3.7%), though this did not reach statistical significance.
Left-sided access increases operator radiation exposure. A left-sided pacemaker is not an absolute contraindication, but it may physically limit access; a shallow needle angle often allows successful placement. A patent LIMA graft is a relative contraindication — the degree of obstruction depends on vessel diameter at the IMA bifurcation compared with the planned sheath’s outer diameter.
3. Room Setup and Arm Positioning
Arm abduction to 90° in a radial arm board is recommended. This lengthens the second segment of the axillary artery, brings it more superficial/anterior, and allows the operator to stay parallel with the vessel.
Keeping the arm at the patient's side (as in femoral access) creates a tendency to pull devices downward, splaying the artery and causing occult bleeding beneath the pectoralis muscle, which tracks down, along the lateral rib cage and may not be readily evident.
For left-sided access, move monitors to the head of the bed or foot of the patient (similar to pacemaker implant setup). For right-sided access, standard room configuration can be maintained.
4. Equipment Checklist
Stiff micropuncture kit
Ultrasound with linear probe and sterile cover
Two Perclose devices (ProGlide or ProStyle)
0.018″ wire (steelcore preferred; avoid V-18 due to risk of branch perforation with its high tip load; Dr. Tayal recommends avoiding 0.014″ wires due to insufficient support for covered stent delivery although some operators may prefer this)
Pre-designated dry closure balloon: 8–10 × 40 mm compliant balloon (shorter balloons risk missing the arteriotomy)
Viabahn covered stents should be in the room — know the required sizes and sheath compatibility
6F and 8F sheaths, JR4 or 3DR diagnostic catheter, stiff exchange-length 0.035″ wire for sheath insertion.
5. Sedation
Conscious sedation is the preferred approach for experienced operators and is standard at high-volume centers (including European practice). General anesthesia may be considered for early-experience cases or when a proctor is teaching.
Experienced operators (≥10 cases) can achieve large-bore sheath insertion and Impella deployment in 7–10 minutes, comparable to transfemoral access times.
6. Axillary Artery Anatomy — Target Zone
The axillary artery is divided into three segments relative to the pectoralis minor muscle:
1st segment (medial to pec minor): branch — superior thoracic artery
2nd segment (posterior to pec minor): branches — thoracoacromial artery, lateral thoracic artery
3rd segment (lateral to pec minor): branches — subscapular artery, anterior and posterior circumflex humeral arteries
The 2nd segment is the recommended target for percutaneous access per the SCAI Position Statement, due to its extrathoracic location, absence of critical branches in the access path, compressibility against the chest wall, and decreased risk of brachial plexus injury (no cord passes anterior to this segment).
Angiographic landmarks for the access zone: puncture between the lateral thoracic artery (first branch going straight caudally off the axillary artery outside the rib cage) and the subscapular artery (identifiable by its proximity to the circumflex humeral arteries near the humeral head). Staying between these two branches places the operator in the 2nd segment in ~95% of cases.
The axillary artery typically measures 6–7 mm in diameter (range 5–8 mm).
7. Safety Wire Strategy
For the first 5–10 cases, femoral access is strongly recommended as the source for the safety wire. Advance a JR4 or 3DR catheter to engage the subclavian, take a baseline angiogram, then advance an 0.018″ wire through the axillary artery.
The 0.018″ wire in the artery serves dual purposes: (1) facilitates ultrasound-guided access by distinguishing artery from vein (important in patients with significant TR, where the vein may appear pulsatile and larger than the artery), and (2) provides a rail for bailout balloon/stent delivery.
Wire entrapment risk: the 0.018″ wire can become entrapped in Perclose sutures. To mitigate this, pull back the 0.018″ wire before deploying pre-closure devices, then re-advance it after pre-closure through an 8F sheath.
Critical: wire the 0.018″ past the arteriotomy site before inserting the large-bore sheath and maintain this wire in place — attempting to wire beyond the sheath after insertion risks dissection.
During the procedure, the 0.018″ wire can remain alongside the coronary guide catheter in the femoral sheath (e.g., 0.018″ wire + 7F guide through an 8F sheath). Some oozing will occur but is not clinically significant.
8. Ultrasound-Guided Puncture Technique
Use ultrasound to identify the brachial plexus (appears as a "ball of grapes" proximally; cords separate as the probe moves laterally — no cord anterior to the 2nd segment).
Mark the skin: (1) where the 0.018″ wire is in the artery, (2) planned skin entry point, and (3) planned arteriotomy site (marked with an "X"). There should be a larger gap between skin entry and arteriotomy than expected based on a shallow angle of approach.
Angle of approach: shallower than femoral access
8. Data to Delivery: Percutaneous Transaxillary Arterial Access and Closure with Dr. Rajiv Tayal
2026/07/06
CathMasters hosts Dr. Amit Goyal, Dr. Li Pang, and Dr. Nazli Okumus discuss the evidence base for percutaneous transaxillary large-bore arterial access and closure with expert faculty Dr. Rajiv Tayal. Approximately 5% of US TAVR cases require alternative access despite lower-profile devices, and with expanding indications for TAVR and mechanical circulatory support (MCS), the absolute number of patients needing non-femoral large-bore access is rising. This "Data to Delivery" episode reviews the comparative outcomes of transaxillary access for TAVR and MCS, the stroke signal and laterality debate, vascular complications of percutaneous versus surgical approaches, brachial plexus injury risk, dwell-time considerations for axillary MCS, and the learning curve for this technique.
CathMasters is for educational purposes only.
CathMasters is for educational purposes only. Music by Elijah K from Pixabay
Pearls
The second segment of the axillary artery is the preferred access site because it is devoid of brachial plexus elements on its anterior surface, is accessible to surgical bailout, and is distant enough from the chest cavity to minimize pneumo/hemothorax risk — a transpectoral approach through pectoralis minor under ultrasound guidance targets this segment (SCAI Position Statement, Seto et al. 2022).
"Bidirectional control is the fundamental principle of large-bore alternative access." Maintain a bailout wire (from the ipsilateral radial or femoral artery) in addition to the wire through the large-bore sheath. This enables proximal balloon tamponade ("dry closure") and rapid covered stent deployment if catastrophic bleeding occurs.
Stroke is the Achilles' heel of transaxillary TAVR — rates are consistently 6–8% across registries (TVT Registry, Hostile Registry, ACCESS study) and appear independent of valve type, laterality, surgical vs. percutaneous approach, or center experience. The 2025 SCAI Consensus Statement notes that other extrathoracic access techniques (transcarotid, transcaval) should be favored over transaxillary when stroke risk is a primary concern.
More vascular complications ≠ more bleeding with percutaneous access. The TVT Registry propensity match showed percutaneous transaxillary access had double the major vascular complications vs. surgical cutdown (3.0% vs. 1.5%), but Southmayd's systematic review found dramatically less major bleeding with percutaneous access (2.7% vs. 18%). This paradox is partly definitional: covered stent placement counts as a vascular complication in percutaneous series but conduit/graft use does not in surgical series.
Axillary Impella enables early ambulation and device stability — the ARMS Registry (102 patients, 10 centers) demonstrated feasibility with complication rates comparable to transfemoral Impella. Devices have been maintained for >14 days percutaneously, though prolonged dwell times increase thrombus risk and may warrant higher ACT targets. After removing the peel-away sheath, the repositioning sheath downsizes to 9F at the tip — leaving the peel-away sheath in place risks a 5–6F gap that promotes thrombus formation and embolization.
Notes
1. Why Transaxillary Access Matters Now
Approximately 25% of TAVR patients have peripheral arterial disease (PAD), and the 2025 SCAI Expert Consensus Statement reports that 4.7% of US TAVR cases require alternative (non-femoral) access despite lower-profile delivery systems.
With TAVR expanding into lower-risk populations and MCS use increasing (high-risk PCI, cardiogenic shock), the absolute demand for non-femoral large-bore access is growing.
Transaxillary access is versatile: it can be performed percutaneously under conscious sedation without general anesthesia or OR activation, and can be deployed emergently (e.g., cardiogenic shock) or electively.
The 2025 SCAI Consensus Statement notes that transaxillary access may carry a higher risk for neurologic complications and recommends that other extrathoracic techniques be favored when feasible.
2. Outcomes: Transaxillary vs. Transfemoral TAVR
Propensity-matched studies show comparable 30-day and 1-year mortality between transaxillary and transfemoral TAVR (Gleason et al., CoreValve trial; Dahle et al., TVT Registry; Kindzelski et al., Cleveland Clinic series).
Procedural success rates for transaxillary TAVR are high (91–100% across observational studies).
The transaxillary approach has emerged as the most common alternative to transfemoral access, surpassing transapical and transaortic routes, which carry higher mortality and bleeding rates.
3. The Stroke Signal
Stroke rates with transaxillary TAVR are consistently elevated at 6–8% across multiple registries:
TVT Registry (Dahle et al.): 6.1% at 30 days with SAPIEN 3
CoreValve Extreme Risk Pivotal Trial: 7.5%
Hostile Registry (Palmerini et al.): 5.9% for transalternative access (92% transaxillary)
ACCESS Study: 8.0% overall (4.0% debilitating)
The 2025 SCAI Consensus concludes that elevated stroke rates appear to be a "class effect" of transaxillary access, independent of valve selection, laterality, surgical vs. percutaneous approach, or center experience.
Proposed mechanisms include: (a) sheath-to-artery ratio effects in a smaller vessel (~6.2 mm average diameter vs. ~8.5 mm for femoral); (b) atherosclerotic embolization during catheter exchanges; (c) right-sided access crossing the innominate artery with inline flow to the right carotid; (d) vertebral artery flow interruption by the large-bore sheath.
Laterality: In the Hostile Registry, right transaxillary stroke was 6.3% vs. 3.7% left, but this difference was not statistically significant (HR 1.14; 95% CI 0.37–3.57; p = 0.82). The ACCESS study similarly found no significant difference by laterality. Left-sided access is generally preferred when feasible, as the sheath may create a partial "embolic shield" across the brachiocephalic artery.
Compared with transcarotid and transcaval access, transaxillary access has consistently higher stroke rates in propensity-matched analyses. Lederman et al. reported a five-fold reduction in stroke/TIA with transcaval vs. transaxillary access (2.9% vs. 13.2%).
4. Vascular Complications: Percutaneous vs. Surgical Cutdown
TVT Registry propensity match (Chung et al., 2022; n = 4,219): Percutaneous transaxillary access had higher major vascular complications (3.0% vs. 1.5%; p = 0.02) but similar life-threatening bleeding (0.3% vs. 0.1%; p = 0.31) compared with surgical cutdown. Percutaneous access was associated with less ICU utilization and more use of conscious sedation.
Southmayd et al. systematic review (2020): Percutaneous large-bore axillary access had dramatically less major bleeding than surgical cutdown (2.7% vs. 18%).
The apparent paradox (more vascular complications but less bleeding) is partly definitional: covered stent placement is classified as a vascular complication in percutaneous series, whereas conduit/graft use in surgical cutdown is not.
Dry closure is the key hemostasis strategy: deploy Perclose devices, and if there is residual bleeding, inflate a balloon proximal to the arteriotomy for tamponade while deploying a covered stent (Viabahn preferred for superior apposition and crush resistance). Covered stent patency in non-diseased axillary arteries is excellent long-term.
The axillary artery has a rich collateral network (subscapular contributories); vascular surgery data suggest that ligation of the artery in the appropriate segment does not cause significant upper extremity ischemia.
5. Other Complications: Brachial Plexus Injury, Pneumo/Hemothorax
Brachial plexus injury was historically the most feared complication (rates as high as 15–20% in the 1970s–80s) when access was obtained in the third segment of the artery (armpit, arm abducted, palpation-guided). The neurovascular bundle is enclosed in a fascial sheath with the artery and vein in this segment, making hematoma-related nerve compression common.
Modern transpectoral access to the second segment under ultrasound guidance has dramatically reduced this risk. The anterior surface of the second segment is devoid of brachial plexus elements. In the ARMS Registry, 3 of 102 patients (2.9%) had brachial plexus symptoms (all C8 tingling), all occurring after multiple days of support. The Cleveland Clinic series (Kindzelski et al.) reported zero brachial plexus injuries.
Pneumo/hemothorax risk increases with access too proximal (first segment), which approaches the thoracic cavity. The second segment is preferred in part because it is more readily accessible for surgical bailout than the first segment.
6. Transaxillary Mechanical Circulatory Support (MCS)
The ARMS Registry (McCabe, Kaki, Tayal et al., 2021): 102 patients across 10 US centers underwent percutaneous axillary Impella CP placement. Successful implantation in 98%. Median device dwell time was 2 days (range 0–35 days). Procedural complications included 10 bleeding events and 1 stroke. Covered stent use was 17%, decreasing with operator experience. Duration of support was independently associated with a 1.1% increased odds of vascular complication per day.
Indications for axillary MCS over femoral include: prohibitive iliofemoral PAD, anticipated need for support >24–48 hours, desire for early patient ambulation, and cardiogenic shock patients who may need escalation of support.
Dwell-time considerations: Devices have been maintained percutaneously for >14 days (up to 30+ days in some cases). Prolonged dwell increases thrombus risk around the access site; higher ACT targets than transfemoral are recommended. Brachial plexus symptoms may increase slightly with prolonged dwell, likely from local inflammation or nuanced bleeding.
Device stability: Axillary Impella tends to be more stable with less need for repositioning compared wi
7. ACS Guidelines Question #2 with Dr. Michelle O’Donoghue
2026/07/03
This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.
The following question refers to Section 5.2.1 of the 2025 ACS Guidelines.
The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by Henry Ford Interventional cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Li Pang, and then by expert faculty Dr. Michelle O’Donoghue.
Dr. O’Donoghue is a cardiologist, senior investigator with the TIMI Study Group, and Associate Professor of Medicine at Harvard Medical School who holds the McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women’s Hospital. She was the Vice Chair of the Writing Committee for the 2025 ACS Guidelines.
QuestionAnswerQuestionAnswer
A 63-year-old woman presented to the emergency room for chest pain. She described having exertional chest pain for the past two months and had an episode of severe pain after dinner 3 days ago. She went to bed and slept it off. She told her children today at a family gathering, and was immediately brought to the ED by her daughter. She has a history of hypertension and hyperlipidemia. She was asymptomatic and normotensive in the ED. Labs show a down-trending troponin and an elevated NT-proBNP but are otherwise unremarkable. Her ECG showed Q waves with ST elevation in V2-V4. She was treated with aspirin and heparin drip, and taken to the cath lab. Coronary angiogram showed complete proximal LAD occlusion with right-to-left collaterals, without significant residual disease elsewhere. She remains asymptomatic and is stable, both hemodynamically and electrically.What is the next best step with regard to reperfusion and anti-thrombotic management?AProceed with primary PCI to LAD BMedical management with aspirin and enoxaparin CMedical management with aspirin and clopidogrelDMedical management with aspirin and ticagrelor
ExplanationThe Correct answer is DIn patients who are stable with STEMI and have a totally occluded infarct-related artery >24 hours after symptom onset and are without evidence of ongoing ischemia, acute severe HF, or life-threatening arrhythmia, PPCI should not be performed due to lack of benefit. (Class 3, LOE B-R)The benefit of PPCI begins to diminish after >12 hours from symptom onset, but there appears to be continued benefit through approximately 24 hours. In stable asymptomatic patients with an occluded artery >48 hours after symptom onset, routine PCI has not been shown to be beneficial in the absence of ongoing ischemia. The relative utility of routine PCI for asymptomatic patients with STEMI between 24 and 48 hours from symptom onset is less rigorously tested.PCI is not recommended for an occluded infarct-related artery if the patient is asymptomatic and has a completed infarct. MACE outcomes were similar in those with an occluded infarct-related artery who underwent medical therapy versus those who underwent PCI 3 to 28 days after an MI (Occluded Artery Trial [OAT]), and results were no different at 7-year follow-up. Similar findings were noted in the DECOPI (Desobstruction Coronaire en Post-Infarctus) trial, which enrolled patients with an occluded artery and Q waves on the ECG presenting 2 to 15 days after symptom onset.However, coronary revascularization should be considered for patients with late presentations with continued signs and symptoms of ischemia, including cardiogenic shock, acute severe HF, persistent angina, and life-threatening arrhythmias. Main TakeawayIn patients who are stable with STEMI who have a totally occluded infarct-related artery >24 hours after symptom onset and are without evidence of ongoing ischemia, acute severe HF, or life-threatening arrhythmia, PPCI should not be performed due to lack of benefit.Guideline Loc.Section 5.2.1
Podcast sponsorship advertising
Start advertising on CathMasters by CardioNerds relevant audience podcasts
You may also like to advertise on these Podcasts

4.8219787
Imperfect Action
Steph Taylor

4.727637592
This Past Weekend w/ Theo Von
Theo Von

4.713055379
The Tim Dillon Show
The Tim Dillon Show

4.116091470
The Tucker Carlson Show
Tucker Carlson Network

4.828116459
Huberman Lab
Scicomm Media

4.240683
To Be The Man
Podcast Heat | Cumulus Podcast Network

4.41511782000
The Ben Shapiro Show
The Daily Wire

4.2155648
TENNIS.com Podcast
TENNIS.com Podcast/Tennis Channel Podcast Network

4.510882780
The Joe Budden Podcast
The Joe Budden Network

4.611699506
The Bulwark Podcast
The Bulwark